. * * window.aa needs to exist and be usable by ANY module's script, * however early it runs - main-nav's script, for one, runs near * the top of

糖心原创

, well before the real search-insights.js * so the download * begins as early as before. Repeat calls share the same downloads, a * failed load is retried on the next call, and the versions / SRI * hashes live only here. * * Algolia Insights is unaffected: window.aa above is still created in * on every page and queues events until search-insights loads. * * window.loadAlgoliaLibs({ priority: 'high' }) (Oct 2026): used by the * /search page, where the first results wait on these libraries. Chrome * gives async scripts low priority, behind images and fonts; this asks * for high instead (fetchpriority). Only the first call for a library * sets its priority - later calls share that download. */ (function (win, doc) { var LIBS = [ { ready: function () { return !!win['algoliasearch/lite']; }, src: 'https://cdn.jsdelivr.net/npm/algoliasearch@5.52.1/dist/lite/builds/browser.umd.js', integrity: 'sha256-I2oYUIvhx1g6l4lTP+yoERbzLIHKzw4AKaBRQPwIeDY=' }, { ready: function () { return !!win.instantsearch; }, src: 'https://cdn.jsdelivr.net/npm/instantsearch.js@4.98.0/dist/instantsearch.production.min.js', integrity: 'sha256-ngmqZk4WBxUw257aMYZayyNBd983INngagv0jI6Ecfs=' } ]; function loadOne(lib, options) { if (lib.ready()) return Promise.resolve(); // One download per library, shared by every caller; reset on // failure so the next call retries just the library that failed. if (lib.pending) return lib.pending; lib.pending = new Promise(function (resolve, reject) { var script = doc.createElement('script'); script.src = lib.src; script.integrity = lib.integrity; script.crossOrigin = 'anonymous'; script.async = true; if (options && options.priority === 'high') script.setAttribute('fetchpriority', 'high'); script.onload = function () { lib.ready() ? resolve() : reject(new Error('Loaded but not available: ' + lib.src)); }; script.onerror = function () { script.remove(); reject(new Error('Could not load ' + lib.src)); }; doc.head.appendChild(script); }); lib.pending.catch(function () { lib.pending = null; }); return lib.pending; } win.loadAlgoliaLibs = function (options) { return Promise.all(LIBS.map(function (lib) { return loadOne(lib, options); })); }; })(window, document); . */ window.hsConversationsSettings = window.hsConversationsSettings || {}; window.hsConversationsSettings.loadImmediately = false; (function (win) { var EVENTS = ['pointerdown', 'keydown', 'touchstart', 'scroll', 'mousemove', 'wheel']; var done = false; /* 19 Oct 2026 - chat widget layout shift (field CLS). Phones fail Core Web Vitals on CLS (p75 ~0.2 site-wide in CrUX for months). Biggest cause found: HubSpot's chat container is fixed to the bottom-right corner and changes size - 100x96 launcher to 282x253 when the welcome message pops up (~5 s after load), and to full screen when a visitor opens the chat. Its top-left corner moves, so Chrome scores it as a layout shift: 0.088 per page view at 360x640 (0.044 at 412x850), on every page. Taps happen inside the chat iframe, so the parent page never sees the input and the open/close shifts count too. Fix: whenever the container's size changes it is made transparent for 400 ms (Chrome doesn't score shifts of invisible elements), then shown again at its new size. Tested on live io1001 at 360x640 in a cookie-less frame: the 0.088 shift no longer appears. The chat itself is unchanged - it just appears 0.4 s later at each resize. Relies on HubSpot's container id; if that changes this does nothing (no error). */ function cloakChatResizes() { var ID = 'hubspot-messages-iframe-container'; function watch(c) { if (c.getAttribute('data-bb-cloak')) return; c.setAttribute('data-bb-cloak', '1'); var last = c.offsetWidth + 'x' + c.offsetHeight, timer = null; new MutationObserver(function () { var size = c.offsetWidth + 'x' + c.offsetHeight; if (size === last) return; last = size; c.style.setProperty('opacity', '0', 'important'); clearTimeout(timer); timer = setTimeout(function () { c.style.removeProperty('opacity'); }, 400); }).observe(c, { attributes: true, attributeFilter: ['style', 'class'], subtree: true, childList: true }); } var found = document.getElementById(ID); if (found) { watch(found); return; } if (!document.body || !('MutationObserver' in win)) return; var mo = new MutationObserver(function () { var c = document.getElementById(ID); if (c) { mo.disconnect(); watch(c); } }); mo.observe(document.body, { childList: true }); setTimeout(function () { mo.disconnect(); }, 30000); } function loadWidget() { var api = win.HubSpotConversations; if (api && api.widget && api.widget.status && api.widget.status().loaded) return; try { cloakChatResizes(); } catch (e) {} if (api && api.widget) api.widget.load(); } function onFirstInteraction() { if (done) return; done = true; EVENTS.forEach(function (type) { win.removeEventListener(type, onFirstInteraction, { passive: true }); }); var start = function () { if (win.HubSpotConversations) loadWidget(); else (win.hsConversationsOnReady = win.hsConversationsOnReady || []).push(loadWidget); }; if ('requestIdleCallback' in win) win.requestIdleCallback(start, { timeout: 1500 }); else setTimeout(start, 200); } EVENTS.forEach(function (type) { win.addEventListener(type, onFirstInteraction, { passive: true }); }); })(window);

糖心原创

Skip to main content
Unlocking the Potential of RNA Therapies in Autism Spectrum Disorder How Definitive Human iPSC-derived Cells are Paving the Way
Webinar

The Potential of RNA Therapies in Autism Spectrum Disorder

In this webinar, Dr Rodney Bowling, Everlum Bio and Dr Malathi Raman offer an expert discussion on how the screening of antisense oligonucleotide (ASO) based RNA therapeutics using highly pure, consistent and scalable precision reprogrammed hiPSC-derived GABAergic neurons is accelerating novel personalised therapies for rare autism spectrum disorders (ASD).
Explore ioGABAergic Neurons
The Potential of RNA Therapies in Autism Spectrum Disorder

Rodney A. Bowling Jr., Ph.D.

Chief Scientific Officer

Everlum Bio

The Potential of RNA Therapies in Autism Spectrum Disorder

Malathi Raman, PhD

Senior Product Manager

糖心原创

In this webinar, Dr Rodney Bowling, Everlum Bio and Dr Malathi Raman offer an expert discussion on how the screening of antisense oligonucleotide (ASO) based RNA therapeutics using highly pure, consistent and scalable precision reprogrammed hiPSC-derived GABAergic neurons is accelerating novel personalised therapies for rare autism spectrum disorders (ASD).
The Potential of RNA Therapies in Autism Spectrum Disorder

Rodney A. Bowling Jr., Ph.D.

Chief Scientific Officer

Everlum Bio

The Potential of RNA Therapies in Autism Spectrum Disorder

Malathi Raman, PhD

Senior Product Manager

糖心原创

Hear from drug development expert, Dr Rodney Bowling (Everlum Bio), to learn how new GABAergic neuronal models are advancing the screening of antisense oligonucleotide (ASO)-mediated RNA therapies for rare autism spectrum disorders (ASD) affecting children.

ASOs have significant potential for neurological disorders as they target specific RNA sequences, either to block the translation of disease-causing proteins or to encourage the production of therapeutic proteins. Human iPSC-derived GABAergic neurons offer a useful physiologically-relevant system to investigate ASO efficiency, but their generation is hindered by heterogeneous populations and lot-to-lot inconsistencies. 

Dr Raman (糖心原创) shares how ioGABAergic Neurons, a new class of precision reprogrammed hiPSC-derived cells, overcomes these limitations, yielding highly pure, consistent and functional populations of mature human iPSC-derived inhibitory GABAergic neurons. Dr Bowling explores how this new class of inhibitory neurons are being applied within ASO-based screening assays and drug discovery workflows for rare ASD.

Learning outcomes: 

  • Discover how ASOs can be used to discover and develop drugs for rare ASD affecting children
    Learn about the need for a consistent, physiologically-relevant and scalable in vitro cellular screening model to identify optimal ASOs for an RNA target for ASD
  • Explore the design considerations for building optimal ASOs, including modifications to improve ASO binding affinity and effectiveness
  • Learn how precision reprogrammed hiPSC-derived ioGABAergic neurons are being applied within ASO screens to discover personalised oligonucleotide-based therapies for rare ASD

 

Explore ioGABAergic Neurons

 

 

Related pages

Products Learn about our range of human iPSC-derived cells for research and drug discovery
Our platform Discover the cell coding platform behind our cells
Contact us Talk to us to learn more about our team and products